TSXV - Delayed Quote CAD

Hemostemix Inc. (HEM.V)

0.0950

0.0000

(0.00%)

At close: May 13 at 2:34:07 PM EDT

Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share

Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, following the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. Per Policy 4.1., Cytoimmune Therapeutics L

Newsfile yesterday

HMTXF
Hemostemix at Invest Stuttgart

Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of investors, financial professionals, and innovators, offering a dynamic platform for Hemostemix to showcase its advancements and connect with potential ACP-01 c

Newsfile 5 days ago

HMTXF
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio

Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest. PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences. The engagement underscores Hemostemix's commitment to expanding its intellectual pr

Newsfile 20 days ago

HMTXF
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial

Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, pitched the treatment of Vascular Dementia with ACP-01 to Wall Street."The specificity of ACP-01 in promotion of angiogenesis, the molecular up-regulation of brain neurotrophic factors, and specific chemokines, strongly suggest ACP-01 may be

Newsfile last month

HMTXF
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire last month

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 2 months ago

NGENF

BPTSY

HMTXF
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASD

Newsfile 2 months ago

HMTXF

AIFF
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announces the sale of 15 ACP-01 Therapy Co

Newsfile 2 months ago

HMTXF
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies

Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its

Newsfile 2 months ago

HMTXF
Hemostemix Licenses CytoImmune's BioReactor Technologies

Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its

Newsfile 2 months ago

HMTXF
Hemostemix Provides Corporate Update

Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment Regulatory Organization ("CIRO"), it is issuing this news release to clarify and provide additional information regarding its previous announcement dated February 10, 2025.On February 10, 2025, Hemostemix announced the engagement of Proconsul Capital Ltd. to provide investor relations services. Th

Newsfile 2 months ago

HMTXF
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification

San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logistics of biologics and pharmaceutical products.The CEIV Pharma Certification ensures the highest standards in the handling, storage, and transportation of biologic

Newsfile 2 months ago

HMTXF
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the ...

Newsfile 2 months ago

HMTXF
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares

Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Common Shares), subject to the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. "The Hemostemix ...

Newsfile 3 months ago

HMTXF
Hemostemix Expands to the Dominican Republic

Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic. Hemostemix has posted an update on Social Media, sharing an inside look at its latest initiative in the Dominican Republic, with a team of cardiologists who have the capacity to treat 110 patients per ...

Newsfile 3 months ago

HMTXF
Hemostemix Announces First Sales Orders for ACP-01

Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments are gaining traction, following its social media campaign and presentations in Puerto Rico. "Advanced sales of ACP-01 enables the purchaser/patient to understand if they are patient one, 10, or 500, and that certainty is helpful," stated Thomas Smeenk, Hemostemix, CEO. ...

Newsfile 3 months ago

HMTXF
Hemostemix Up-lists to TradeGateExchange in Germany

Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced trading on the TradeGateExchange.De under symbol 2VF0 today, January 27, 2025."Listing on the TradeGateExchange.De enables Hemostemix to investors in the Europe, the EU, UK, to buy into their Fountain of Youth and longevity, directly. As management and directors, we have invested greater ...

Newsfile 3 months ago

HMTXF
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico

Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence trading on the OTCQB under symbol HMTXF today, January 23, 2025, while the Company presents "Welcome to Your Fountain of Youth!" at the Sequire Investor Summit at 11:00 a.m."Listing on the OTCQB enables US investors to buy into their 'Fountain of Youth' and ...

Newsfile 3 months ago

HMTXF
Hemostemix Announces Grant of Stock Options

Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on January 22, 2025, subject to regulatory approval, a total of 2,085,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 1,815,000 vest immediately and 270,000 ..

Newsfile 3 months ago

HMTXF
Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact

Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly anticipated Puerto Rico Investor Summits:Sequire Investor Summit: January 22-23 at the Condado Vanderbilt Hotel.CytoImmune-hosted Event: January 24 at CytoImmune's state-of-the-art facility in San Juan, Puerto Rico.Thomas Smeenk, President & CEO of Hemostemix, will deliver an engaging presentation highlig

Newsfile 3 months ago

HMTXF

Performance Overview

Return	HEM.V	S&P/TSX Composite index (^GSPTSE)
YTD	+35.71%	+4.05%
1-Year	+137.50%	+15.08%
3-Year	-73.61%	+27.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hemostemix Inc. (HEM.V)

Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share

Hemostemix at Invest Stuttgart

Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio

Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture

RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies

Hemostemix Licenses CytoImmune's BioReactor Technologies

Hemostemix Provides Corporate Update

Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification

Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares

Hemostemix Expands to the Dominican Republic

Hemostemix Announces First Sales Orders for ACP-01

Hemostemix Up-lists to TradeGateExchange in Germany

Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico

Hemostemix Announces Grant of Stock Options

Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact

Performance Overview